Form 8-K - Current report:
SEC Accession No. 0001140361-24-043670
Filing Date
2024-10-18
Accepted
2024-10-18 09:29:09
Documents
14
Period of Report
2024-10-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20035737x4_8k.htm   iXBRL 8-K 35584
2 EXHIBIT 99.1 ny20035737x4_ex99-1.htm EX-99.1 16431
  Complete submission text file 0001140361-24-043670.txt   194383

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20241018.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20241018_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20241018_pre.xml EX-101.PRE 16042
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20035737x4_8k_htm.xml XML 4227
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241379035
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)